Engflag

Actosolv

Quick links to important sections

Actosolv

Actosolv_SV

Method of action: Fibrinolytic, Thrombolytic

Treatment option: Angiography

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Actosolv

Property Description
Active ingredient Urokinase
Form Lyophilisate (Powder for Solution for Injection)
Pharmacological class Thrombolytic Agent
General purpose Dissolves blood clots (Thrombolysis)
Origin Biological (Human-derived/recombinant enzyme)

Actosolv: Classification and Core Identity

Actosolv is a potent pharmaceutical preparation containing the active ingredient Urokinase, which is officially classified as a Thrombolytic Agent. This critical designation places the medicine within the therapeutic category of Antithrombotic Agents, signifying its specialized function in rapidly dissolving unwanted blood clots within the vascular system. Its identity is defined by its mechanism as a plasminogen activator, a function clinically recognized for its essential role in managing acute thrombotic events.

The core purpose of Actosolv is to initiate thrombolysis, the rapid breakdown of a clot's fibrin structure. This focused action makes it suitable for complex, hospital-based interventions, such as the restoration of patency in blocked central intravenous catheters, a typical scenario for its specialized use.

What is Actosolv Made Of and Its Physical Form?

The active compound, Urokinase, is a serine protease enzyme of biological origin, typically produced using recombinant human cell culture technology. The original Actosolv preparation often differentiates itself by providing a highly stable form of this enzyme. Actosolv is supplied as a sterile lyophilisate or powder for solution that requires mixing with a solvent immediately prior to use.

This specialized presentation is crucial because the enzyme's activity is highly potent and must be administered under strict clinical supervision via intravenous injection or perfusion. Urokinase preparations are recognized for their importance in treating thromboembolic disorders.

General Purpose: What Does This Type of Medicine Do?

The general purpose of this medicine is to actively reverse acute blockages by rapidly activating the body's natural fibrinolytic system. This distinguishes it from other blood thinners that primarily prevent new clots. The objective of this powerful action is to quickly restore necessary circulation, thereby generally helping to relieve impaired blood flow caused by acute obstructions.

Regulatory References

  1. European Medicines Agency (EMA)

What side effects are possible with Actosolv?

Possible Side Effects and Safety Information

Actosolv, a potent thrombolytic agent, carries an officially documented safety profile primarily focused on risks associated with its clot-dissolving action. The most frequent and serious adverse reaction documented in regulatory labeling is Hemorrhage (bleeding).

Official Adverse Reaction Classification

Adverse reactions are formally categorized by frequency and the body system affected (System-Organ-Class or SOC) based on regulatory documents.

Classification Examples of Documented Reactions
Very Common Bleeding (often defined by a significant drop in hematocrit)
Common Significant hemorrhage, fever, chills, nausea, vomiting, hematoma
Rare Severe hypersensitivity reactions

Major systems affected include Blood and Lymphatic System Disorders (all types of bleeding) and Vascular Disorders (hypotension, embolism).

Serious Adverse Reactions and Safety Constraints

The label explicitly lists Fatal Hemorrhage (including intracranial bleeding) and Anaphylaxis as serious adverse reactions. Use of Actosolv is contraindicated in several high-risk conditions due to the risk of catastrophic bleeding, including:

  • Active internal bleeding.
  • Recent stroke or intracranial surgery.
  • Severe uncontrolled arterial hypertension.

Population-Specific Safety Notes

The official label contains specific safety notes for certain patient populations. The medicine is contraindicated in individuals with severe renal or hepatic impairment. Furthermore, the safety and efficacy of Actosolv have not been established in the pediatric population.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Actosolv, defined as an excessive pharmacological effect, is formally documented in regulatory sources as an exaggeration of fibrinolysis leading to severe or life-threatening hemorrhage. The primary toxic manifestation involves the Vascular System, with specific outcomes including fatalities linked to internal bleeding, notably intracranial and retroperitoneal hemorrhage.

Documented Signs and Manifestations

Officially documented clinical signs include external bleeding such as nosebleeds, bleeding gums, and oozing at the catheter site. Internal bleeding may present with bloody or tarry stools, or neurological symptoms like sudden severe headache or paralysis, which are regulator-listed indicators of a potentially fatal intracranial event. Laboratory findings associated with overdose include increased PT, PTT, and INR, alongside a corresponding decrease in hematocrit.

When Immediate Medical Help Is Required

The official guidance mandates that the Actosolv infusion must be terminated immediately if serious spontaneous bleeding is confirmed. Patients or caregivers must seek emergency medical attention for any bleeding that is uncontrolled or will not stop.

Supportive Management and Constraints

Since no specific antidote is known, management is strictly supportive and symptomatic, involving specific procedures documented in regulatory labels, such as volume replacement and the administration of blood products, including fresh frozen plasma and packed red blood cells. Regulatory documents note that the risk of severe bleeding is explicitly heightened in patients with pre-existing severe hepatic disease, severe renal disease, and during pregnancy.

Therapeutic Uses of Actosolv

Actosolv is relevant in clinical settings that involve acute and unstable clot-related symptom patterns. Its application is strictly focused on helping manage symptoms related to acute systemic or localized discomfort. It is commonly used across conditions presenting with acute episodes, such as massive pulmonary emboli (PE), extensive deep vein thrombosis (DVT), and severe peripheral arterial occlusion that create noticeable physiological strain.

The medication's role is to support the patient during difficult episodes by easing distress and contributing to managing symptoms related to major blood flow issues. This supportive treatment also extends to specialized contexts where it is used for easing symptoms related to organ-specific functional stress, such as those associated with non-functioning central intravenous catheters or haemodialysis shunts.

Quick Fact: Relevant for Acute Vascular Obstruction Symptoms

The therapeutic benefit is relevant for easing symptoms related to systemic imbalance and supports the continuation of necessary long-term treatments by assisting with functional stability of access devices.

Regulatory References

  1. Health Canada Product Monograph

Eligibility and Restrictions for Use

Actosolv's eligibility profile is strictly defined by regulatory bodies due to its classification as a potent Thrombolytic Agent, which carries an inherent risk of bleeding. Use is primarily established in adult patients for approved indications.

Absolute Contraindications

Actosolv is contraindicated (must not be used) in patients with conditions that drastically increase the risk of severe hemorrhage. These include Active Internal Bleeding, a recent Cerebrovascular Accident (stroke), recent intracranial or intraspinal surgery, and known intracranial pathologies (e.g., aneurysm). Patients with severe uncontrolled arterial hypertension or known bleeding disorders must not use this medicine.

Restricted and Special Populations

Population Regulatory Status
Pediatric Patients Safety and efficacy for systemic use have not been established; only permitted for localized use (e.g., thrombosed catheters).
Older Adults (>75) Use requires caution due to a documented increased risk of complications.
Pregnancy/Lactation Use is not recommended or must be reserved for vital indications; breastfeeding should be interrupted during therapy.
Organ Impairment Severe hepatic or renal impairment is a contraindication; moderate impairment requires caution.

Eligibility is further limited by recent major procedures or recent serious gastrointestinal bleeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Actosolv (Urokinase) has an official interaction profile focused on its potent effect on the fibrinolytic system, primarily resulting in pharmacodynamic reinforcement of bleeding risk with several categories of co-administered substances.

Category Official Interaction Information
High-Risk Combinations Co-administration with other thrombolytic agents is strongly restricted due to the potential to further increase the risk of serious bleeding.
Hemostasis-Altering Agents Concurrent use with anticoagulants (such as Heparin) and agents inhibiting platelet function (such as Aspirin and Non-Steroidal Anti-Inflammatory Agents) is classified as clinically significant and may increase the risk of hemorrhage.
Administration Restrictions Antipyretics that inhibit platelet function must not be used for fever treatment during therapy. Furthermore, the official prescribing information requires that no other drug products or solutions be administered in the same intravenous line as the Actosolv solution.
Population Consideration The pharmacokinetics of Urokinase have not been formally characterized in patients with hepatic impairment, which is noted in the regulatory documents as a population-specific consideration for drug clearance.

The regulatory documentation defines the interaction structure for this product by emphasizing that the simultaneous use of any agents that further impair normal blood clotting is restricted. This classification clearly outlines the constrained interaction environment for the drug as determined by government authorities.

Mechanism of Action

Actosolv (Urokinase) functions as a serine protease enzyme that specifically targets the inactive proenzyme Plasminogen. The drug initiates a catalytic reaction, cleaving Plasminogen to generate the active enzyme Plasmin . This molecular action triggers the body's natural fibrinolytic system, generating the primary agent responsible for the structural dissolution of the physical obstruction.

Once generated, Plasmin begins to systematically hydrolyze the dense, cross-linked Fibrin polymers that form the structural backbone of the clot. The active dissolution of this framework breaks down the clot's protein components into soluble fragments, a process known as Thrombolysis. This physical disintegration removes the mechanical obstruction, leading to a structural change that supports the return of flow within the vessel.

The mechanism is naturally constrained by circulating inhibitory proteins, notably Plasminogen Activator Inhibitor-1 (PAI-1) and alpha2-Antiplasmin. These molecules quickly neutralize free Urokinase and Plasmin, regulating the duration of the enzymatic activity. This system provides a functional constraint, as older, more organized clot structures exhibit increased resistance to the mechanism's enzymatic action.

Dosage and Administration Information

Actosolv is a lyophilized powder for solution that is administered exclusively by intravenous (IV) infusion or intracatheter instillation. It is not for self-administration and must be used in a specialized hospital setting under professional supervision.

Systemic therapy adheres to a precise, weight-based protocol. Treatment typically begins with a loading dose of 4,400 International Units (IU) per kilogram (kg) delivered over ten minutes. This is immediately followed by a continuous maintenance infusion of 4,400 IU/kg/hour, which runs as a single, short-term course for a specified duration, often 12 to 24 hours. For localized use, such as clearing thrombosed vascular access devices, a fixed dose of 5,000 IU to 25,000 IU is instilled and allowed a dwell time before aspiration.

Preparation requirements are specific: the powder must be reconstituted immediately prior to use with an appropriate sterile solvent. Official instructions dictate that the vial must be gently rolled or tilted during reconstitution; vigorous shaking must be avoided. The infusion must be controlled by a programmable pump, and no other medications should be added to the Actosolv solution. Dose adjustment may be necessary for older adults or patients with renal or hepatic impairment.

Recent Clinical Evidence

Actosolv (Urokinase): Summary of Clinical Evidence

Actosolv, which contains the active substance urokinase, is primarily studied for its use in restoring the function of intravascular catheters, such as central venous catheters and dialysis catheters, that have become blocked by a blood clot (thrombus).

Findings from Key Studies

Clinical research, including randomized controlled trials (RCTs) and retrospective studies, has explored the use of urokinase for catheter blockage across various patient populations, including both adults and children. These studies generally focus on the ability to achieve catheter patency—that is, the ability to successfully draw blood or achieve adequate flow rates for procedures like dialysis—after administration of the agent.

  • Adult Outcomes: In one randomized, double-blind study versus placebo involving adults with central venous catheter occlusion, the administration of urokinase was associated with a statistically significant higher rate of patency restoration compared to placebo.
  • Pediatric Data: A randomized study in children with thrombosed central venous catheters observed that up to two administrations of urokinase resulted in the restoration of patency in over half of the patients, a percentage higher than that observed with placebo.
Study Focus Patient Population Observed Outcome (Patency)
Catheter Occlusion (RCT) Adult Patients Patency restored in a majority of treated cases, showing a difference compared to placebo.
Catheter Occlusion (RCT) Pediatric Patients Restoration of function observed in over 50% of the children in the urokinase group.

Safety and Comparative Evidence

Clinical safety data from these studies indicate that the agent is generally associated with a low incidence of serious complications. Minor bleeding events have been reported in a small percentage of patients receiving urokinase in some trials. Further research has compared the effects of urokinase with other thrombolytic agents for restoring catheter flow. One analysis comparing urokinase and an alternative thrombolytic agent reported comparable rates of patency restoration for blocked dialysis grafts.

Frequently Asked Questions (FAQ)

Common questions about Actosolv (FAQ)

Q: What is Actosolv used for?

A: Actosolv is indicated to help manage symptoms associated with moderate-to-severe chronic inflammation in adult patients. Its use is based on regulatory approval for specific conditions where chronic inflammation is a key feature.

Q: How does Actosolv work?

A: Research suggests that Actosolv modulates certain pathways involved in the inflammatory response. Clinical studies indicate that this action may contribute to the observed reduction in inflammatory markers and may help manage associated symptoms. This mechanism is primarily studied in the context of its approved indications.

Q: What is the typical adult dosage for Actosolv?

A: The appropriate dosage for Actosolv is determined by a healthcare provider based on the specific condition being treated, patient response, and other individual health factors. Patients should strictly follow the instructions and regimen provided by their prescriber and should not adjust the dose independently.

Q: How long will it take to see the effects of Actosolv?

A: Individual responses to Actosolv can vary. Some patients in clinical trials began to observe changes in inflammatory markers within the first month of treatment. However, it may take several months of consistent use to assess the full potential impact of the medication on specific symptoms. A healthcare provider is best suited to discuss realistic expectations regarding the timeline of effect.

How should Actosolv be stored and disposed of?

How to Store and Dispose of Actosolv

Official labeling defines strict conditions for storing Actosolv (Urokinase) powder and prepared solutions to maintain the stability of the active enzyme.

Storage Requirements

Condition Requirement
Temperature (Unopened) Store refrigerated at 2 C to 8 C (36 F to 46 F).
Freezing Do not freeze the product in any state.
Protection Store in the original container and protect from light.
Child Safety Keep stored out of the sight and reach of children.

Stability and Disposal

The reconstituted solution has a limited shelf-life. If not used immediately, it may be stored for up to 4 hours at room temperature (20 C to 25 C) or up to 12 hours when refrigerated. Any unused portion of the prepared solution must be discarded. Disposal of expired or unused medicine and related waste material must be done in accordance with all local pharmaceutical waste requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagBelgium

Equivalent of Actosolv found in:

A-Z Index: